Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [
Human epididymis protein 4
Ovarian epithelial carcinoma
Positron emission tomography
Tumour biomarkers, CA-125 antigen
Tumour burden
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
21
03
2021
accepted:
25
08
2021
revised:
11
08
2021
pubmed:
30
9
2021
medline:
17
3
2022
entrez:
29
9
2021
Statut:
ppublish
Résumé
Accurate assessment of disease extent is required to select the best primary treatment for advanced epithelial ovarian cancer patients. Estimation of tumour burden is challenging and it is usually performed by means of a surgical procedure. Imaging techniques and tumour markers can help to estimate tumour burden non-invasively. 2-[ We included 66 patients who underwent 2-[ wb_MTV and wb_TLG were found to be significantly correlated with serum CA125 and HE4 concentrations. The strongest correlation was observed between HE4 and wb_MTV40 (r = 0.62, p < 0.001). Pearson's correlation coefficients between peritoneal carcinomatosis MTV40 and tumour markers were 0.61 (p < 0.0001) and 0.29 (p = 0.02) for HE4 and CA125 respectively. None of these tumour markers showed a positive correlation with tumour load outside the abdominal cavity assessed by volumetric parameters. HE4 performs better than CA125 to predict metabolic tumour burden in high-grade epithelial ovarian cancer before primary treatment. 2-[18F]FDG PET/CT volumetric parameters arise as feasible tools for the objective assessment of tumour load and its anatomical distribution. These results support the usefulness of HE4 and PET/CT to improve the stratification of these patients in clinical practice. • In patients with high-grade advanced ovarian epithelial carcinoma, both CA125 and HE4 correlate to whole-body tumour burden assessed by PET/CT before primary treatment. • HE4 estimates peritoneal disease much better than CA125. • PET/CT volumetric parameters arise as feasible tools for the objective assessment of tumour load and its anatomical distribution.
Identifiants
pubmed: 34586465
doi: 10.1007/s00330-021-08305-x
pii: 10.1007/s00330-021-08305-x
doi:
Substances chimiques
Biomarkers, Tumor
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2200-2208Informations de copyright
© 2021. European Society of Radiology.
Références
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
Prat J (2015) Staging Classification for cancer of the ovary, fallopian tube, and peritoneum. Obstet Gynecol 126:171–174. https://doi.org/10.1097/AOG.0000000000000917
doi: 10.1097/AOG.0000000000000917
pubmed: 26241270
Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953. https://doi.org/10.1056/NEJMoa0908806
doi: 10.1056/NEJMoa0908806
pubmed: 20818904
Colombo N, Sessa C, Du Bois A et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. https://doi.org/10.1093/annonc/mdz062
doi: 10.1093/annonc/mdz062
pubmed: 31046082
Chéreau E, Ballester M, Selle F et al (2010) Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 202:178.e1-178.e10. https://doi.org/10.1016/j.ajog.2009.10.856
doi: 10.1016/j.ajog.2009.10.856
Pignata S, Cannella L, Leopardo D et al (2011) Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol 22:viii40–viii44. https://doi.org/10.1093/annonc/mdr470
Plotti F, Guzzo F, Schirò T et al (2019) Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. Int J Gynecol Cancer 29:768–771. https://doi.org/10.1136/ijgc-2019-000211
doi: 10.1136/ijgc-2019-000211
Zwakman N, van de Laar R, Van Gorp T et al (2017) Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. J Gynecol Oncol 28: https://doi.org/10.3802/jgo.2017.28.e7
Simmons AR, Baggerly K, Bast RC (2013) The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) 27(6):548–56
Kemppainen J, Hynninen J, Virtanen J, Seppänen M (2019) PET/CT for evaluation of ovarian cancer. Semin Nucl Med 49:484–492. https://doi.org/10.1053/j.semnuclmed.2019.06.010
doi: 10.1053/j.semnuclmed.2019.06.010
pubmed: 31630732
Gallicchio R, Nardelli A, Venetucci A et al (2017) F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer. Eur J Radiol 93:107–113. https://doi.org/10.1016/j.ejrad.2017.05.036
doi: 10.1016/j.ejrad.2017.05.036
pubmed: 28668403
Ruiz-Hernández G, Delgado-Bolton RC, Fernández-Pérez C et al (2005) Meta-analysis of the diagnostic efficacy of FDG-PET in patients with suspected ovarian cancer recurrence. Rev Esp Med Nucl 24:161–173. https://doi.org/10.1157/13073787
doi: 10.1157/13073787
pubmed: 15847783
Ruiz-Hernández G, Delgado-Bolton RC, Fernández-Pérez C et al (2005) Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer. Rev Esp Med Nucl 24:113–126. https://doi.org/10.1157/13071687
doi: 10.1157/13071687
pubmed: 15745682
An H, Lee EYP, Chiu K, Chang C (2018) The emerging roles of functional imaging in ovarian cancer with peritoneal carcinomatosis. Clin Radiol 73:597–609. https://doi.org/10.1016/j.crad.2018.03.009
doi: 10.1016/j.crad.2018.03.009
pubmed: 29685803
Suppiah S, Chang WL, Hassan HA et al (2017) Systematic review on the accuracy of positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging in the management of ovarian cancer: is functional information really needed? World J Nucl Med 16:176–185
doi: 10.4103/wjnm.WJNM_31_17
pubmed: 28670174
pmcid: 5460299
Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J (2019) The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma. Cancer Biomark 27:1–6. https://doi.org/10.3233/cbm-190904
doi: 10.3233/cbm-190904
Muallem MZ, Sehouli J, Richter R et al (2020) Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. Int J Gynecol Cancer 30:62–66. https://doi.org/10.1136/ijgc-2019-000778
doi: 10.1136/ijgc-2019-000778
pubmed: 31744887
Evangelista L, Palma MD, Gregianin M et al (2015) Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/ computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. J Turk Ger Gynecol Assoc 16:137–144. https://doi.org/10.5152/jtgga.2015.15251
doi: 10.5152/jtgga.2015.15251
pubmed: 26401105
pmcid: 4560469
Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354. https://doi.org/10.1007/s00259-014-2961-x
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Han S, Suh CH, Kim YJ et al (2018) Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in ovarian cancer: a systematic review and meta-analysis. Ann Nucl Med 32:669–677. https://doi.org/10.1007/s12149-018-1289-1
doi: 10.1007/s12149-018-1289-1
pubmed: 30101392
Yousefi M, Dehghani S, Nosrati R et al (2020) Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. Cell Oncol 43:515–538. https://doi.org/10.1007/s13402-020-00513-9
doi: 10.1007/s13402-020-00513-9
Sugarbaker PH (2010) Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 101:713–724. https://doi.org/10.1002/jso.21484
doi: 10.1002/jso.21484
pubmed: 20512948
Chung HH, Kwon HW, Kang KW et al (2012) Preoperative [18 F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol 23:28. https://doi.org/10.3802/jgo.2012.23.1.28
doi: 10.3802/jgo.2012.23.1.28
pubmed: 22355464
pmcid: 3280063
Yamamoto M, Tsujikawa T, Fujita Y et al (2016) Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy. Cancer Sci 107:478–485. https://doi.org/10.1111/cas.12890
doi: 10.1111/cas.12890
pubmed: 26789906
pmcid: 4832857
Lee JW, Cho A, Lee J-H et al (2014) The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 41:1898–1906. https://doi.org/10.1007/s00259-014-2803-x
doi: 10.1007/s00259-014-2803-x
pubmed: 24852188
Mayoral M, Fernandez-Martinez A, Vidal L et al (2016) Prognostic value of 18F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol 35:88–95. https://doi.org/10.1016/j.remn.2015.08.005
doi: 10.1016/j.remn.2015.08.005
pubmed: 26541072
Kim C-Y, Jeong SY, Chong GO et al (2015) Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 136:498–504. https://doi.org/10.1016/j.ygyno.2014.12.032
doi: 10.1016/j.ygyno.2014.12.032
pubmed: 25557270
Plotti F, Scaletta G, Capriglione S et al (2017) The role of HE4, a novel biomarker, in predicting optimal cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 27:696–702. https://doi.org/10.1097/IGC.0000000000000944
doi: 10.1097/IGC.0000000000000944
pubmed: 28406844
Shen Y, Li L (2016) Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Tumor Biol 37:14765–14772. https://doi.org/10.1007/s13277-016-5335-0
doi: 10.1007/s13277-016-5335-0
Tsuboyama T, Tatsumi M, Onishi H et al (2014) Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses. Invest Radiol 49:524–531. https://doi.org/10.1097/RLI.0000000000000050
doi: 10.1097/RLI.0000000000000050
pubmed: 24637584
Konishi H, Takehara K, Kojima A et al (2014) Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 24:1190–1194. https://doi.org/10.1097/IGC.0000000000000180
doi: 10.1097/IGC.0000000000000180
pubmed: 24987918